| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
GSK, Sanofi eye late-stage trial of Covid-19 vaccine in coming weeks following positive update
StockMarketWire.com
|
Pharma giants GlaxoSmtihKline and Sanofi said they would move to a phase 3 trial of their Covid-19 vaccine in the coming weeks after a phase 2 trial showed 'strong' rates of immune responses in all adult age groups.
'The phase 2 study interim results show that the adjuvanted recombinant vaccine candidate triggered a strong immune response amongst adults of all age groups with 95% to 100% seroconversion rates and neutralizing antibodies that were comparable to those generated by natural infection,' GSK said.
'The phase 3 trial is expected to enrol more than 35,000 adult participants from a broad range of countries and will assess the efficacy of two vaccine formulations including the D614 (Wuhan) and B.1.351 (South African) variants,' it added.
Pending positive phase 3 outcomes and regulatory reviews, the vaccine is expected to be approved in the fourth quarter of 2021.
Story provided by StockMarketWire.com
|
|
|
|
|
|
